Sci-Tech World Equatorial Guinea
SEE OTHER BRANDS

Reporting on science and technology news in Equatorial Guinea

Sci-Tech World Equatorial Guinea: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech World Equatorial Guinea.

Press releases published on June 25, 2025

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile …

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements

DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025 …

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the …

Wowza Acquires AVA Intellect as it Accelerates Commitment to AI-First Innovation Strategy

Wowza Acquires AVA Intellect as it Accelerates Commitment to AI-First Innovation Strategy

Acquisition aligned with Wowza’s vision for intelligent video infrastructure, bringing agent-based automation to streaming orchestration and optimization. Wowza appoints AVA Intellect co-founder Mike Vitale as Head of Intelligence at Wowza. DENVER, June 25 …

Coin Casino Launches Instant Crypto Withdrawal System with No ID Verification for U.S. Players

Coin Casino Launches Instant Crypto Withdrawal System with No ID Verification for U.S. Players

SAN JUAN, Puerto Rico, June 25, 2025 (GLOBE NEWSWIRE) -- Coin Casino, a licensed crypto gaming platform, today announced the rollout of its Instant Crypto Withdrawal System, a major update that allows registered players to cash out winnings instantly and …

New Jitterbit Partner Program Enables Global Channel to Deliver Enterprise Automation, AI Agents

New Jitterbit Partner Program Enables Global Channel to Deliver Enterprise Automation, AI Agents

ALAMEDA, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Jitterbit, a global leader in accelerating business transformation for enterprise systems, today announced the global expansion of its partner program and new Jitterbit University partner curricula. …

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve …

Agillic approved as ‘SKI’ vendor for the Danish public sector

Agillic approved as ‘SKI’ vendor for the Danish public sector

Press release – Copenhagen, 25 June 2025 – Agillic A/S Agillic has been approved as a SKI vendor under the framework agreement ’02.06 standard software’, allowing organisations across state, regions, and municipalities to include Agillic’s marketing …

Haal meer uit de cloud met expertise van AWS en een MSP

Haal meer uit de cloud met expertise van AWS en een MSP

Amsterdam, Nederland, Juni 2025, Sean Tilley, Director of Sales EMEA bij 11:11 Systems, een provider van beheerde infrastructuuroplossingen, gaat dieper in op de basisinformatie van data voor de moderne onderneming en hoe die bedrijven in staat stelt te …

Transformez le cloud en levier de succès en alliant AWS à l’expertise des MSP

Transformez le cloud en levier de succès en alliant AWS à l’expertise des MSP

Paris, France, juin 2025, Sean Tilley, directeur commercial senior chez 11:11 Systems, un MSP reconnu, examine le rôle essentiel des données dans l’entreprise moderne et leur importance pour son fonctionnement. Alors que la complexité et la richesse de l’ …

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC …

Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy

Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment Initial proof-of- …

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, 2025, regarding the request to retract the …

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le mardi 24 juin 2025, relative à la demande …

New Jitterbit Partner Program Enables Global Channel to Deliver Enterprise Automation, AI Agents

New Jitterbit Partner Program Enables Global Channel to Deliver Enterprise Automation, AI Agents

FRANKFURT, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Jitterbit, a global leader in accelerating business transformation for enterprise systems, today announced the global expansion of its partner program and new Jitterbit University partner curricula. …

NextBillion.ai selects TomTom Orbis Maps to deliver enhanced enterprise-grade solutions globally

NextBillion.ai selects TomTom Orbis Maps to deliver enhanced enterprise-grade solutions globally

AMSTERDAM, June 25, 2025 (GLOBE NEWSWIRE) -- TomTom (TOM2), the location technology specialist, and NextBillion.ai, a leading provider of AI-powered mapping solutions for enterprise, today announced an expanded partnership to deliver precise route …

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today …

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney …

Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides

Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides

Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service